Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

31.41 +0.01 (+0.03%)
Streaming Delayed Price Updated: 1:21 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 376,458
Open 31.39
Bid (Size) 31.40 (8,700)
Ask (Size) 31.41 (3,500)
Prev. Close 31.40
Today's Range 31.39 - 31.41
52wk Range 19.05 - 32.56
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC ↗
Via Chartmill
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shows Strong Growth and a Bullish Technical Setup ↗
Via Chartmill

Performance

YTD
+35.7%
+35.7%
1 Month
+0.3%
+0.3%
3 Month
+36.2%
+36.2%
6 Month
+29.6%
+29.6%
1 Year
+42.0%
+42.0%

More News

Read More
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen ↗
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment ↗
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup ↗
Via Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Beats Q4 Estimates, Issues Conservative 2026 Outlook ↗
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗
Via Chartmill
News headline image
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
From Angelini Pharma; Catalyst Pharmaceuticals
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup ↗
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Catalyst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Catalyst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Catalyst Pharmaceuticals, Inc. - Common Stock trade on?
Catalyst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock is CPRX on the Nasdaq Stock Market
What is the current price of Catalyst Pharmaceuticals, Inc. - Common Stock?
The current price of Catalyst Pharmaceuticals, Inc. - Common Stock is 31.41
When was Catalyst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Catalyst Pharmaceuticals, Inc. - Common Stock was at 06/24/26 01:21 PM ET
What is the market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock is 3.23B
How many shares of Catalyst Pharmaceuticals, Inc. - Common Stock are outstanding?
Catalyst Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.